Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 11
Submit an article Journal homepage
675
Views
34
CrossRef citations to date
0
Altmetric
Drug Evaluations

Yellow fever vaccine: past, present and future

Anna H Roukens Leiden University Medical Center, Department of Infectious Diseases, PO Box 9600, 2300 RC Leiden, Netherlands +31 71 5262613; +31 71 5266758; [email protected]
, MD &
Leo G Visser Leiden University Medical Center, Department of Infectious Diseases, PO Box 9600, 2300 RC Leiden, Netherlands +31 71 5262613; +31 71 5266758; [email protected]
, MD PhD
Pages 1787-1795 | Published online: 10 Oct 2008

Bibliography

  • Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, editors, Vaccines. Philadelphia: Saunders; 1999. p. 815-79
  • World Health Organisation. Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 2003;40:349-59
  • Monath TP. Treatment of yellow fever. Antiviral Res 2008;78:116-24
  • Carter HR. Yellow fever: an epidemiological and historical study of its place of origin. Williams & Wilkins Co, Baltimore; 1931
  • Augustin. History of yellow fever. New Orleans: Searcy and Pfaff; 1909
  • Chang GJ, Cropp BC, Kinney RM, et al. Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus. J Virol 1995;69:5773-80
  • Lepiniec L, Dalgarno L, Huong VT, et al. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol 1994;75:417-23
  • Wang E, Weaver SC, Shope RE, et al. Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology 1996;225:274-81
  • Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular persprective on the introduction of yellow fever virus into the Americas. PLoS Pathog 2007;3:e75. Published online 18 May 2007, doi:10.1371/journal.ppat.0030075
  • Reed W, Agramonte A. Landmark article. Feb 16, 1901. The etiology of yellow fever. An additional note. JAMA 1983;250:649-58
  • Stokes A, Bauer JH, Hudson NP. The transmission of yellow fever to Macacus rhesus. Rev Med Virol 2001;11:141-8
  • Sellards AW. The behaviour of the virus of yellow fever in monkeys and mice. Proc Natl Acad Sci USA 1931;17:339-43
  • Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunzation. J Exp Med 1937;65:787-800
  • Mar ID, Niang I, Guicheney A, et al. Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965). Ann Pediatr (Paris) 1967;143:181-91
  • Monath TP. Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-74
  • Perraut R, Girault G, Moreau JP. Stability-related studies on 17D yellow fever vaccine. Microbes Infect 2000;21:33-8
  • World Health Organisation. Technical Report Series, No 872. Requirements for yellow fever vaccine (Requirements for biological substances No 3, revised 1995). 1998:30-68
  • Stokes A, Bauer JH, Hudson NP. Experimental transmission of yellow fever to laboratory animals. Am J Trop Med 1928;8:103
  • Gould EA, Buckley A, Barrett ADT, Cammack N. Neutralizing (54K) and nonneutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 1986;67:591-5
  • Pincus S, Mason PW, Konishi E, et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever virus encephalitis. Virology 1992;187:290-7
  • Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973;25:539-44
  • National Institute for Biological Standards and Control. WHO Reference Reagent. The 1st International Reference Preparation for Anti-Yellow Fever Serum, Monkey NIBSC code: YF Instructions for use. Available from: http://www.nibsc.ac.uk/documents/ifu/YF.pdf [Last accessed 2008 August 28]
  • Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two yellow fever vaccines. Am J Trop Med Hyg 1999;60:1045-50
  • Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999;12:867-71
  • Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895-900
  • World Health Organisation, Outbreak news: Yellow fever, Brazil. Wkly Epidemiol Rec 2008;83:61-8
  • Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered Yellow Fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008;3:e1993. Published online 23 April 2008, doi:10.1371/journal.pone.0001993
  • Hepburn MJ, Kortepeter MG, Pittman PR, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006;24:2843-9
  • Available from: http://who.int/ith
  • Available from: http://www.cdc.gov/travel/contentYellowBook.aspx
  • World Health Organisation, IHR, 2005. International certificate of vaccination or prophylaxis. On-line resource. Available from: http://www.who.int/csr/ihr/icvp/en/index.html [Last accessed 2007 August 28]
  • Wilder-Smith A, Hill DR, Freedman DO. The revised international health regulations 2005: impact on yellow fever vaccination in clinical practice. Am J Trop Med Hyg 2008;78:359-60
  • World Health Organisation, Yellow fever in Africa and South America, 2006. Wkly Epidemiol Rec 2008;83:69-76
  • Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999;103:698-701
  • National Coordination Centre for Traveller's Health (LCR). National guidelines for vaccination and malaria prophylaxis for travellers. Amsterdam: LCR; 2008
  • Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98-104
  • Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-2
  • Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91-7
  • Zhou Q, Liu DW, Shi Y, et al. Adverse effects of attenuated yellow fever vaccine with multiple organ injury-a case report. Zhonghua Yi Xue Za Zhi 2005;85:936
  • Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 2005;98:653-6
  • Doblas A, Domingo C, Bae HG, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 2006;36:156-8
  • Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007;25:8480-5
  • Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007;101:967-71
  • Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-63
  • Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1:207-14
  • Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40
  • Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008;197:266-9
  • Pulendran B, Miller J, Querec TD, et al. Case of Yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES. J Infect Dis 2008;198:500-7
  • Massad E, Coutinho FAB, Burattini MN, et al. Yellow fever vaccination: how much is enough? Vaccine 2005;23:3908-14
  • Martins RM, Galler R, Freire MS, et al. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 2005; 23:3908-14]. Vaccine 2007;25:10-11
  • Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004;364:936
  • Goujon C, Tohr M, Feuille V, et al. Good tolerance and efficacy of yellow fever vaccine among subjects carriers of human immunodeficiency virus [abstract 32]. Presented at the 4th International Conference on Travel Medicine; 23 – 27 April; Acapulco, Mexico
  • Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004;18:825-7
  • Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002;85:131-4
  • Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993;87:337-9
  • Suzano CE, Amaral E, Sato HK, Papaiordanou PM. Campinas Group on Yellow Fever Immunization during Pregnancy. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006;24:1421-6
  • Cavalcanti DP, Salomão MA, Lopez-Camelo J, Pessoto MA. Campinas Group of Yellow Fever Immunization during Pregnancy. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007;12:833-7
  • Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993;168:1520-3
  • No authors listed. Yellow fever preparedness. Lancet 2008;371:786
  • World Health Organization, Oubreak news: yellow fever, Paraguay. Wkly Epidemiol Rec 2008;83:105-8
  • Roberts L. Infectious disease. Resurgence of yellow fever in Africa prompts counterattack. Science 2007;316:1109
  • Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94
  • Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301
  • Redfield RR, Innis BL, Scott RM, et al. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985;254:3203-6
  • Warrell MJ, Warrell DA, Suntharasamai P, et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post exposure prophylaxis. Lancet 1983;2:301-4
  • Fox JP, Luty Kossobudski S, Fonseca da Cunha J. Field studies on the immune response to 17D yellow fever virus. Relation to virus substrain, dose and route of inoculation. Am J Hyg 1943;38:113-38
  • Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26:3197-208
  • Gaspar LP, Mendes YS, Yamamura AM, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008;150:57-62
  • Pugachev KV, Monath TP, Guirakhoo F. Chimeric vaccines against Japanese encephalitis, dengue, and West Nile. In: Levine MM, Kaper JB, Rappuoli R, et al. editors, New generation vaccines. 3d edition. New York Basel: Marcel Dekker; 2004. p. 559-71
  • Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004;78:4761-75
  • Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006;103:6694-9
  • Bredenbeek PJ, Molenkamp R, Spaan WJ, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006;345:299-304
  • Puchachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005;18:387-94
  • British Society for Rheumatology. Vaccinations in the immunocompromised person. Guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies (1-2 edition) [report]. The British Society for Rheumatology; 28 Jan 2002
  • Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002;34:1369-78
  • Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63
  • Marianneau P, George-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 2001;358:84-5
  • Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2:60-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.